Bruton Tyrosine Kinase (BTK) Inhibitors in Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia - Episode 3
Kami J. Maddocks, MD, discusses the investigation of noncovalent BTK inhibitors in mantle cell lymphoma.
Kami J. Maddocks, MD, professor, the Division of Hematology at The Ohio State University, professor, member, the Leukemia Research Program, the OSUCCC – James, discusses the investigation of noncovalent BTK inhibitors in mantle cell lymphoma (MCL).
The role of noncovalent BTK inhibitors in patients with MCL continues to evolve, according to Maddocks. Most patients treated on clinical trials evaluating the use of noncovalent BTK inhibitors have either progressed on prior covalent BTK inhibitors or stopped treatment due to toxicity, Maddocks says. Data have suggested that noncovalent BTK inhibitors can potentially be leveraged in those who progress on covalent BTK inhibitors, Maddocks adds.
The phase 3 BRUIN-MCL-321 trial (NCT04662255) is investigating the noncovalent BTK inhibitor pirtobrutinib (LOXO-305) vs physician’s choice of covalent BTK inhibitors, including ibrutinib (Imbruvica), acalabrutinib (Calquence), and zanubrutinib (Brukinsa), in pretreated patients with MCL, Maddocks concludes.